Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth
Abstract Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials as a promising therapeutic modality....
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Portfolio
2023-05-01
|
| Serier: | Scientific Reports |
| Online adgang: | https://doi.org/10.1038/s41598-023-34965-4 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|